Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastases

Gepubliceerd: 22-08-2016 Laatst bijgewerkt: 15-05-2024

NSCLC spreads using the blood. Tumour cells in the circulating system are called circulating tumour cells, and are deemed the cause of metastases, making CTCs a mayor factor in therapy efficacy and prognosis. We believe that the different...

Ethische beoordeling	Niet van toepassing
Status	Anders
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON29203

Bron
Nationaal Trial Register

Verkorte titel
CTC Autopsy study

Aandoening

NSCLC niet kleincellig longcarcinoom, longkanker
lungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor cel

Ondersteuning

Primaire sponsor: University Medical Centre Groningen
Overige ondersteuning: University Medical Centre Groningen

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

- heterogeneity and mutational load measurements in all compartments. These can subsequently be compared to one another.

Toelichting onderzoek

Doel van het onderzoek

NSCLC spreads using the blood. Tumour cells in the circulating system are called circulating tumour cells, and are deemed the cause of metastases, making CTCs a mayor factor in therapy efficacy and prognosis. We believe that the different compartments (original tumour, metastases and CTCs) will have differences in the genetic make up that could give insight in the metastatic process and shed light on so called 'trunc' and 'branch' mutations. To study all different compartments in detail, we will ask terminal patients to participate in a so called obduction study. After a patients death, we will obtain biopsies of the metastases and the primary tumour. When this is done the patients body will be returned to the family for burial.

Onderzoeksopzet

-

Onderzoeksproduct en/of interventie

Terminal patients are included after their informed consent and that of their families is received. We will withdraw some blood for analysis on CTCs. After the participants death, we will perform a warm autopsy to obtain samples from the primary tumour and its metastases. The patients body will subsequently be returned to the family for burial.

Contactpersonen

Publiek

UMCG
Department of Pulmonary Disease, Box 30001
H.J.M. Groen
Groningen 9700 RB
The Netherlands

+31 (0)50 3616161

Wetenschappelijk

UMCG
Department of Pulmonary Disease, Box 30001
H.J.M. Groen
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Patients with a histologically/cytologically proven pulmonary malignancy.

2. Patients have to have a non-curable disease state, without curative treatment options

3. Signed informed consent

4. Patients family has asserted their acceptance of the patients participation

5. Patients using anticoagulants such as fraxodi or acenocoumarol are allowed

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. No growth factor medication

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Anders
Blindering:	Open / niet geblindeerd

Controle:	N.v.t. / onbekend

Deelname

Nederland

Status:	Anders
(Verwachte) startdatum:	01-10-2016
Aantal proefpersonen:	30
Type:	Onbekend

Ethische beoordeling

Niet van toepassing

Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 45251
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL5862
NTR-old	NTR6042
CCMO	NL59037.042.16
OMON	NL-OMON45251

Resultaten